Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing
May 29, 2023 20:57 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) is pleased to announce that it has closed its previously announced...
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
May 01, 2023 22:44 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting
April 20, 2023 12:47 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the...
Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023
April 17, 2023 18:18 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is pleased to announce that it has been invited to present at...
Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs
March 30, 2023 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of Red Cloud Securities (“Red Cloud”) and...
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
March 22, 2023 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to...
Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates
March 10, 2023 20:36 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend...
Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
January 26, 2023 23:45 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a scientific presentation at the 6th Annual DDR...
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
November 23, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
November 17, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...